Flag of the European Union EU Clinical Trials Register Help

Clinical trials for BASFI

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    54 result(s) found for: BASFI. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2005-002320-34 Sponsor Protocol Number: M01 Start Date*: 2005-10-12
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Randomized controlled 12 months trial with etanercept (enbrel ®) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on ...
    Medical condition: The proposed study is designed to get first data on efficacy and safety of etanercept in the treatment of patients with moderate to severe early axial Spondyloarthritis (SpA) with disease duration...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001894-41 Sponsor Protocol Number: AS0006 Start Date*: 2015-10-16
    Sponsor Name:UCB BIOSCIENCES GmbH
    Full Title: PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) WITHOUT X-RAY ...
    Medical condition: ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) WITHOUT X-RAY EVIDENCE OF ANKYLOSING SPONDYLITIS (AS) AND OBJECTIVE SIGNS OF INFLAMMATION
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10076297 Non-radiographic axial spondyloarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-000431-14 Sponsor Protocol Number: M16-098 Start Date*: 2017-11-13
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis
    Medical condition: Active Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) DE (Completed) FI (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Completed) PT (Completed) NL (Completed) BE (Completed) HU (Completed) PL (Completed) SE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001555-37 Sponsor Protocol Number: CC-10004-AS-001 Start Date*: 2012-09-04
    Sponsor Name:Celgene Corporation
    Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of apremilast (CC-10004) in the treatment of active ankylosing spondyl...
    Medical condition: Ankylosing spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) SK (Completed) NL (Completed) ES (Completed) PL (Completed) SE (Completed) CZ (Completed) AT (Completed) BG (Completed) FR (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001549-41 Sponsor Protocol Number: 0881A3-402-WW Start Date*: 2005-11-25
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: A Randomised, Double-Blind Study Comparing the Safety and Efficacy of Etanercept with Sulphasalazine in Subjects with Ankylosing Spondylitis
    Medical condition: Subjects with Ankylosing Spondylitis (AS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) FI (Completed) AT (Completed) DE (Completed) GB (Completed) DK (Completed) SE (Completed) PT (Completed) IE (Completed) GR (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003932-11 Sponsor Protocol Number: I1F-MC-RHBV Start Date*: 2016-04-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients with ...
    Medical condition: Radiographic Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10041672 Spondylitis ankylosing LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-003937-84 Sponsor Protocol Number: I1F-MC-RHBW Start Date*: 2016-03-07
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 16 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients with Radiogr...
    Medical condition: Radiographic Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10041672 Spondylitis ankylosing LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) NL (Completed) DE (Completed) ES (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003064-13 Sponsor Protocol Number: AS0010 Start Date*: 2019-06-11
    Sponsor Name:UCB Biopharma SRL
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
    Medical condition: Nonradiographic axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10076297 Non-radiographic axial spondyloarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) FR (Completed) HU (Completed) GB (GB - no longer in EU/EEA) BG (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002306-64 Sponsor Protocol Number: Ritux-AS-01 Start Date*: 2006-12-28
    Sponsor Name:Charité Universitaetsmedizin
    Full Title: Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab
    Medical condition: Moderate to severe ankylosing spondylitis who have had an inadequate response to or do not tolerate conventional therapy including NSAIDs, DMARDs and TNF alpha inhibitors
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002967-28 Sponsor Protocol Number: ABATACEPT-AS-01 Start Date*: 2007-10-19
    Sponsor Name:Charité University Medicine
    Full Title: Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis
    Medical condition: T cell responses have been demonstrated against proteoglycan (an important cartilage protein) in human arthritides including ankylosing spondylitis. We suggest that a chronic, probably T cell media...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000643-40 Sponsor Protocol Number: 50307 Start Date*: 2014-01-10
    Sponsor Name:Instituto de Medicina Molecular
    Full Title: A multicentre, randomized, double-blind, parallel–group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy, in improving dactylitis and enthesi...
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004532-18 Sponsor Protocol Number: M10-239 Start Date*: 2014-11-12
    Sponsor Name:Abbott
    Full Title: A Multi-Center, Open-Label Efficacy, Safety, and Pharmacokinetic Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-016587-36 Sponsor Protocol Number: P06451 Start Date*: 2010-03-15
    Sponsor Name:Schering Plough, S.A
    Full Title: Artritis de cadera asociada a la EA. Eficacia y Seguridad del tratamiento precoz con Infliximab (Remicade®)
    Medical condition: Espondilitis anquilosante
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003432-72 Sponsor Protocol Number: DRESS-PS Start Date*: 2018-10-23
    Sponsor Name:Sint Maartenskliniek
    Full Title: Randomised controlled trial of dose reduction and withdrawal strategies of TNF inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis. “Dose REduction Strategy Study of TNF inhibitors in Ps...
    Medical condition: Adults diagnosed with Psoriatic Arthritis en Axial Spondyloarthritis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007637-39 Sponsor Protocol Number: ENRADAS-01 Start Date*: 2008-12-17
    Sponsor Name:Charité - Campus Mitte
    Full Title: Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) – a prospective randomised controlled trial - Amendment 2
    Medical condition: Ankylosing spondylitis patients (according to mod. New York criteria) who have have active disease at inclusion defined as BASDAI question 2 (related to back pain) >= 4 (VAS, range 0-10) without NS...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002556 Ankylosing spondylitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002349-35 Sponsor Protocol Number: 0881A3-102090 Start Date*: 2006-09-30
    Sponsor Name:Wyeth Farma S.A.
    Full Title: Estudio piloto randomizado, doble ciego, multicéntrico a 12 semanas para evaluar el efecto de etanercept 100mg y 50mg semanales en sujetos con espondilitis anquilosante. A 12-week randomized, do...
    Medical condition: Espondilitis anquilosante Ankylosing spondylitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004961-42 Sponsor Protocol Number: BC-6226 Start Date*: 2020-08-06
    Sponsor Name:Ghent University Hospital
    Full Title: SPondyloArthritis: inducing drug-free Remission by early TNF-Alpha bloCkade Under guidance of Single cell RNA sequencing and epigenetic profiling
    Medical condition: peripheral spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10051265 Spondyloarthropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2017-004700-22 Sponsor Protocol Number: 1608185 Start Date*: 2018-02-26
    Sponsor Name:CHU SAINT-Etienne
    Full Title: Rotation or Change of Biotherapy After TNF blocker treatment failure for axial Spondyloarthritis: The ROC-SpA study
    Medical condition: axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004254-22 Sponsor Protocol Number: PASTOR2018 Start Date*: 2020-03-20
    Sponsor Name:Charite University
    Full Title: Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients with Psoriatic ArthritiS PresenTing with Axial InvOlvement - a Randomized, Double-Blind, Placebo-Controlled, Mult...
    Medical condition: Psoriatic Arthritis with axial (spinal) involvement
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037166 Psoriatic spondylitis LLT
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003636-21 Sponsor Protocol Number: GLPG0634-CL-223 Start Date*: 2017-01-26
    Sponsor Name:Galapagos NV
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 12 weeks to subjects with active ankylosing spondylitis
    Medical condition: ankylosing spondylitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) CZ (Completed) ES (Completed) BG (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 17:33:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA